US Patent

US10603384 — Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative

Formulation · Assigned to Aicuris GmbH and Co KG · Expires 2033-02-28 · 7y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a pharmaceutical composition containing a specific dihydroquinazoline derivative, used for intravenous administration, in combination with certain excipients.

USPTO Abstract

The invention relates to pharmaceutical compositions, particularly for intravenous administration, containing {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid in combination with at least one of the cyclodextrin excipients, lysine and arginine; the method for its production; and its use in methods of treatment of and/or as a prophylactic for illnesses, particularly its use as an antiviral, preferably against cytomegaloviruses.

Drugs covered by this patent

Patent Metadata

Patent number
US10603384
Jurisdiction
US
Classification
Formulation
Expires
2033-02-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Aicuris GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.